KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $19.1 billion.

  • Regeneron Pharmaceuticals' Non-Current Assets rose 22.53% to $22.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 billion, marking a year-over-year increase of 22.53%. This contributed to the annual value of $19.1 billion for FY2024, which is 40.42% up from last year.
  • As of FY2024, Regeneron Pharmaceuticals' Non-Current Assets stood at $19.1 billion, which was up 40.42% from $13.6 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year Non-Current Assets high stood at $19.1 billion for FY2024, and its period low was $7.4 billion during FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Non-Current Assets averaged around $15.3 billion, with its median value being $13.6 billion (2023).
  • Data for Regeneron Pharmaceuticals' Non-Current Assets shows a peak YoY spiked of 54.65% (in 2021) over the last 5 years.
  • Regeneron Pharmaceuticals' Non-Current Assets (Yearly) stood at $7.4 billion in 2020, then soared by 54.65% to $11.4 billion in 2021, then grew by 16.73% to $13.3 billion in 2022, then rose by 2.03% to $13.6 billion in 2023, then surged by 40.42% to $19.1 billion in 2024.